Opendata, web and dolomites

THERAPROBES SIGNED

Biodegradable fluorescent nanoprobes for early detection of (pre)malignant lesions of the gastrointestinal tract

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THERAPROBES project word cloud

Explore the words cloud of the THERAPROBES project. It provides you a very rough idea of what is the project "THERAPROBES" about.

surveillance    random    silica    tumor    patients    intervention    nanoprobes    diagnosing    true    miss    gastrointestinal    ubiquitously    endoscopy    accurately    compromises    marker    tract    size    survival    fsn    errors    accumulate    treatments    quality    active    accurate    lesions    reliably    resection    biopsy    diagnosis    agents    rate    scales    impacting    poor    malignant    ablation    lesion    detection    disease    specificity    visualization    life    inter    symptomatic    sampling    requiring    progress    clinical    operator    routine    accuracy    progression    minus    biodegradable    sensitive    aggressive    sensitivity    imaging    variability    lack    directing    curative    successful    chance    negatively    site    augmented    near    time    physician    paradigm    misses    solely    white    optical    detect    inherent    strategy    patient    therapeutic    permeability    recur    improves    endoscopic    detected    unmet    subtle    tremendous    contrast    light    vascular    fluorescent    fsns    rates    sites    amenable    gitract    regular    appearance    asymptomatic    gi    50    systemic    diagnostic    applicable    decrease    clinically    risk    25    outcomes    delineation    critical    treatment    80    33   

Project "THERAPROBES" data sheet

The following table provides information about the project.

Coordinator
PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 187˙572 €
 EC max contribution 187˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 187˙572.00

Map

 Project objective

Accurate diagnosis of (pre)malignant gastrointestinal (GI)-tract lesions is critical for patient survival. Early detection of asymptomatic disease of the GItract improves the chance of curative intervention by 50−80% as compared to poor five-year survival rates for symptomatic advanced malignant disease. Regular endoscopic surveillance in high-risk patients misses 25% of (pre)malignant lesions – the most clinically relevant marker for malignant progression. This clinically significant miss rate is due to the subtle appearance of such lesions under white-light endoscopy and sampling errors inherent to a random-biopsy surveillance paradigm, which increases inter-operator variability and compromises diagnostic accuracy. Even when malignant disease is detected, lack of sensitive contrast agents compromises delineation of the true extent of the lesion. These factors decrease the physician’s ability to achieve successful therapeutic intervention through resection or ablation. About 33% of GI-tract lesions progress or recur at or near the therapeutic site, commonly requiring aggressive yet often non-curative, systemic treatments negatively impacting the patients’ quality of life. There is an unmet clinical need for endoscopic optical imaging approaches that reliably detect those lesions with high sensitivity and specificity. To develop a clinically viable strategy, I propose to use biodegradable, fluorescent silica nanoprobes (FSN) that provide real-time visualization of the lesions over a range of scales during routine endoscopy. Since FSNs accumulate at the tumor sites solely due to their size and increased vascular permeability, no active targeting is needed, making these imaging agents ubiquitously applicable. Endoscopy augmented with FSNs has tremendous potential for better outcomes particularly in high-risk patients by accurately diagnosing and directing treatment specifically to early lesions at a time when patients are amenable to curative therapeutic intervention.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPROBES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAPROBES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

GLORIOUS (2019)

Digital Poetry in Today’s Russia: Canonisation and Translation

Read More  

BirthControlEnvirons (2019)

Contraception meets the environment: everyday contraceptive practices, politics, and futures in a toxic age

Read More